# EDGAR Filing Document

**Accession Number:** 0002065241
**File Stem:** 0000914190-26-000035
**Filing Date:** 2026-3
**Character Count:** 8812
**Document Hash:** 7fd1b7414aca18f1982399810e0d7759
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0000914190-26-000035.hdr.sgml**: 20260304

**ACCESSION NUMBER**: 0000914190-26-000035

**CONFORMED SUBMISSION TYPE**: 3

**PUBLIC DOCUMENT COUNT**: 2

**CONFORMED PERIOD OF REPORT**: 20260301

**FILED AS OF DATE**: 20260304

**DATE AS OF CHANGE**: 20260304

**REPORTING-OWNER**: 

**OWNER DATA:**
- **COMPANY CONFORMED NAME:** Crouse Steven C.
- **CENTRAL INDEX KEY:** 0002065241

**ORGANIZATION NAME:**

**FILING VALUES:**
- **FORM TYPE:** 3
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 000-17272
- **FILM NUMBER:** 26723390

**MAIL ADDRESS:**
- **STREET 1:** 5980 HORTON STREET, STE 600
- **CITY:** EMERYVILLE
- **STATE:** CA
- **ZIP:** 94608
**ISSUER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** BIO-TECHNE Corp
- **CENTRAL INDEX KEY:** 0000842023
- **STANDARD INDUSTRIAL CLASSIFICATION:** BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 411427402
- **STATE OF INCORPORATION:** MN
- **FISCAL YEAR END:** 0630

**BUSINESS ADDRESS:**
- **STREET 1:** 614 MCKINLEY PL N E
- **STREET 2:** SUITE 1500
- **CITY:** MINNEAPOLIS
- **STATE:** MN
- **ZIP:** 55413
- **BUSINESS PHONE:** 612-379-8854

**MAIL ADDRESS:**
- **STREET 1:** 614 MCKINLEY PLACE NE
- **CITY:** MINNEAPOLIS
- **STATE:** MN
- **ZIP:** 55413

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** TECHNE CORP /MN/
- **DATE OF NAME CHANGE:** 19920703

## Ex-24

```

POWER OF ATTORNEY

The undersigned hereby constitutes and appoints James
Hippel, Anna Weispfenning, Andrew Nick,
Sara Tucher or either of them acting alone, the undersigned's true
and lawful attorneys-in-fact and agent with full power of substitution
and resubstitution, for the undersigned and in the undersigned's name,
place and stead, in any and all capacities, to sign any or all Forms
3, Forms 4 and Forms 5 relating to beneficial ownership of securities
of Bio-Techne Corporation (the "Issuer"), to file the same, with all
exhibits thereto and other documents in connection therewith, with
the Securities and Exchange Commission and to deliver a copy of the
same to the Issuer, granting unto said attorney-in-fact and agent
full power and authority to do and perform each and every act and
thing requisite and necessary to be done in and about the premises,
as fully to all intents and purposes as the undersigned might or
could do in person, hereby ratifying and confirming all said
attorneys-in-fact and agent, or his substitute or substitutes, may
lawfully do or cause to be done by virtue thereof. The undersigned
acknowledges that the foregoing attorney-in-fact, in serving in such
capacity at the request of the undersigned, is not assuming any of
the undersigned's responsibilities to comply with Section 16 of the
Securities Exchange Act of 1934.

This Power of Attorney shall remain in effect until such time as the
undersigned is no longer subject to the provisions of Section 16 of
the Securities Exchange Act of 1934 with respect to securities of
the Issuer.

IN WITNESS WHEREOF, the undersigned has caused this Power of
Attorney to be executed as of this 4th day of March, 2026.

/s/ Steven C. Crouse

```

### UNITED STATES SECURITIES AND EXCHANGE COMMISSION
**Washington, D.C. 20549**

## FORM 3

### INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

[ ] Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

---

| | | |
|:---|:---|:---|
| **1. Name and Address of Reporting Person**<sup>*</sup><br>Crouse Steven C.<br><sub>(Last) (First) (Middle)</sub><br>614 MCKINLEY PLACE NE<br><sub>(Street)</sub><br>MINNEAPOLIS, MN 55413<br><sub>(City) (State) (Zip)</sub> | **3. Issuer Name and Ticker or Trading Symbol**<br>BIO-TECHNE Corp [ TECH ] | **5. If Amendment, Date of Original Filed (Month/Day/Year)**<br>  |
| **2. Date of Event Requiring Statement (Month/Day/Year)**<br>2026-03-01 | **4. Relationship of Reporting Person(s) to Issuer**<br>(Check all applicable)<br>[ ] Director   [ ] 10% Owner<br>[X] Officer (give title below)   [ ] Other (specify below)<br>_President - Diag & Spatial Bi_ | **6. Individual or Joint/Group Filing (Check Applicable Line)**<br>[X] Form filed by One Reporting Person<br>[ ] Form filed by More than One Reporting Person |

---

## Table I - Non-Derivative Securities Beneficially Owned

---

|  |  |  |  |
| --- | --- | --- | --- |
| 1. Title of Security | 2. Amount of Securities Beneficially Owned | 3. Ownership Form | 4. Nature of Indirect Beneficial Ownership |
| Common Stock | 5894 | D |  |

---

## Table II - Derivative Securities Beneficially Owned

---

|  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- |
| 1. Title of Derivative Security | 2. Date Exercisable and Expiration Date (Month/Day/Year) | 2. Date Exercisable and Expiration Date (Month/Day/Year) | 3. Title and Amount of Underlying Securities | 3. Title and Amount of Underlying Securities | 4. Conversion or Exercise Price | 5. Ownership Form | 6. Nature of Indirect Beneficial Ownership |
| 1. Title of Derivative Security | Date Exercisable | Expiration Date | Title | Amount or Number of Shares | 4. Conversion or Exercise Price | 5. Ownership Form | 6. Nature of Indirect Beneficial Ownership |
| Restricted Stock Units | <sup>(2)</sup> | <sup>(2)</sup> | Common Stock | 1588 | <sup>(1)</sup> | D |  |
| Restricted Stock Units | <sup>(3)</sup> | <sup>(3)</sup> | Common Stock | 1800 | <sup>(1)</sup> | D |  |
| Restricted Stock Units | <sup>(4)</sup> | <sup>(4)</sup> | Common Stock | 1379 | <sup>(1)</sup> | D |  |
| Restricted Stock Units | <sup>(5)</sup> | <sup>(5)</sup> | Common Stock | 3737 | <sup>(1)</sup> | D |  |
| Restricted Stock Units | <sup>(6)</sup> | <sup>(6)</sup> | Common Stock | 6529 | <sup>(1)</sup> | D |  |
| Stock Option (right to buy) | <sup>(7)</sup> | 2028-04-01 | Common Stock | 3856 | $97.13 | D |  |
| Stock Option (right to buy) | <sup>(7)</sup> | 2028-08-06 | Common Stock | 19032 | $120.46 | D |  |
| Stock Option (right to buy) | <sup>(8)</sup> | 2029-08-15 | Common Stock | 24560 | $94.52 | D |  |
| Stock Option (right to buy) | <sup>(9)</sup> | 2030-08-15 | Common Stock | 12649 | $84.61 | D |  |
| Stock Option (right to buy) | <sup>(10)</sup> | 2031-05-01 | Common Stock | 7327 | $73.46 | D |  |
| Stock Option (right to buy) | <sup>(11)</sup> | 2034-08-15 | Common Stock | 17133 | $74.91 | D |  |
| Stock Option (right to buy) | <sup>(12)</sup> | 2035-06-02 | Common Stock | 5434 | $48.61 | D |  |
| Stock Option (right to buy) | <sup>(13)</sup> | 2035-08-15 | Common Stock | 19151 | $53.60 | D |  |

---

### Footnotes:

(1) Each restricted stock unit represents a contingent right to receive one share of Bio-Techne common stock.

(2) 794 restricted stock units vest on 5/1/2026 and 5/1/2027.

(3) 600 restricted stock units vest on each of 6/2/2026, 6/2/2027 and 6/2/2028.

(4) 1,379 restricted stock units vest on 8/15/2026.

(5) 1,868 restricted stock units vest on 8/15/2026 and 1,869 restricted stock units vest on 8/15/2027.

(6) 2,176 restricted stock units vest on each of 8/15/2026 and 8/15/2028; and 2,177 restricted stock units vest on 8/15/2027.

(7) 100% vested.

(8) Options to purchase 6,140 shares vest on each of 8/15/2023, 8/15/2024, 8/15/2025 and 8/15/2026.

(9) Options to purchase 3,162 shares vest on each of 8/15/2024, 8/15/2026 and 8/15/2027; and options to purchase 3,163 shares vest on 8/15/2025.

(10) Options to purchase 1,832 shares vest on each of 5/1/2025, 5/1/2026 and 5/1/2028; and options to purchase 1,831 shares vest on 5/1/2027.

(11) Options to purchase 4,283 shares vest on each of 8/15/2025, 8/15/2027 and 8/15/2028; and options to purchase 4,284 shares vest on 8/15/2026.

(12) Options to purchase 1,359 shares vest on each of 6/2/2026 and 6/2/2028; and options to purchase 1,358 shares vest on each of 6/2/2027 and 6/2/2029.

(13) Options to purchase 4,788 shares vest on each of 8/15/2026, 8/15/2027 and 8/15/2029; and options to purchase 4,787 shares vest on 8/15/2028.

**Signature:** /s/ Andrew Nick as Attorney-in-Fact for Steven C. Crouse pursuant to Power of Attorney filed herewith.  
**Date:** 2026-03-04

### Remarks:

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

**Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.**